pdufa.bio
Home › Decisions › VRDN 2026-06-29

VRDN FDA decision — Jun 29, 2026

✓ APPROVED

Viridian Therapeutics Inc. — Lumvoa (veligrotug-vvze) - (THRIVE-2) · Thyroid Eye Disease (TED).

Run-up into the decision (T-120 → T+5)

PDUFA 6/29/26$33.78$13.31/12/26
Daily close, T-120 (1/12/26) through T+5. Run-up high $33.78 on 1/21/26, low $13.3 on 5/1/26 (T-120 to T-1). FDA decision 6/29/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-29
OutcomeApproved
Drug / candidateLumvoa (veligrotug-vvze) - (THRIVE-2)
CompanyViridian Therapeutics Inc.
120-day run-up (T-120→T-1)-40.7%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio